School of Medicine

Wayne State University School of Medicine

Mission/About

The Neuro-Oncology program and clinic is a multidisciplinary clinical and research effort including specialists in neurology and neuro-oncology, neurosurgery, radiation oncology, medical oncology, neuroradiology, neuropathology, pharmacy, positron emission tomography (PET) imaging, and molecular and glial biology. The neuro-oncology program provides diagnosis and management of metastatic and non-metastatic complications of systemic cancer and primary CNS tumors. It is an integral part of the Karmanos Cancer Institute.

Dr Geoffrey Barger has served as attending physician at the Detroit Medical Center and Karmanos Cancer center from 1990 to the present. He has organized and directed the weekly Neuro-Oncology conference since 1990. Dr Barger has served as the Co-Director of the Neuro-Oncology Multidisciplinary Team of the Karmanos Cancer Center from 2003 to the present. Dr Sandeep Mittal has served as Co-Director of the Neuro-Oncology Multidisciplinary Team from 2006 to the present. Other key members of the group include  Dr William Kupsky (neuropathology), Dr Murali Guthikonda (neurosurgery), Dr Natasha Robinette and Dr Alit Yousif (neuroradiology), Dr Harold Kim (radiation oncology), Dr Mark Szlaczky (pharmacy), and Dr Csaba Juhasz (PET).

While the main focus of the group has been to provide the best possible clinical care to all our patients, including the use of genetic characteristics of individual patient’s tumors to help define the best treatment, there is an increasing effort on clinical trials which use this approach and laboratory and imaging research. Two new members of our group, Dr Nicholas Szerlip (neurosurgery) and Dr Abhirami Hallock (radiation oncology), will help with such projects.  The National Cancer Institute has funded Drs Juhasz, Barger, and Mittal to study AMT PET imaging since 2007. AMT PET imaging is proving useful in differentiating tumor from radiation injury, a notoriously difficult problem. AMT PET may also help determine response to treatment and help us identify useful new treatments for primary brain tumors.

             

 

 

.